Cancer clinical trials in the region Occitanie
369 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Lymphoma
#NCT06911502
Required histologic types
B cell lymphoma
Required histologic sub types
Follicular lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Chemotherapy
Monoclonal antibodies
5 recruiting sites
Celgene
Phase 3
Lung cancer
#NCT04613596
#2023-508922-83-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
16 recruiting sites
Mirati Thérapeutique Inc.
Phase 3
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT06465953
#2023-510155-37
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Secondary MDS
Required genetic anomalies
IDH1/2
Required number of previous lines of therapy
None
Required IPSS-M prognostic scores
Low
Moderately low
Moderately high
High
Very high
Excluded previous treatments
Chemotherapy
Allogeneic stem cell transplant
6 recruiting sites
Servier
Phase 3
Head and neck cancer
#NCT06496178
#2023-510322-32-00
Required histologic types
Oral cavity
Oropharynx
Hypopharynx
Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
16 recruiting sites
Merus
Phase 3
CLL & Richter's syndrome
#NCT07277231
#2025-524366-21-00
Required histologic types
CLL (Chronic Lymphocytic Leukemia)
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
4 recruiting sites
BeOne Medecines
Phase 3
Head and neck cancer
#NCT06129864
Required histologic types
Oral cavity
Oropharynx
Hypopharynx
Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Radiochemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Surgery
Radiotherapy
8 recruiting sites
AstraZeneca
Phase 3
Kidney cancer
#NCT07011719
#2024-515023-11-00
Required histologic types
Clear cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
9 recruiting sites
Arcus Biosciences
Phase 3
Lymphoma
#NCT06091865
#2022-502785-25-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None
Required immunophenotypic profiles
CD20
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
15 recruiting sites
Regeneron Pharmaceuticals
Phase 3
Lymphoma
#NCT06091865
#2022-502785-25-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None
Required immunophenotypic profiles
CD20
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
15 recruiting sites
Regeneron Pharmaceuticals
Phase 3
Breast cancer
#NCT05512364
#2022-501453-36-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
1
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Surgery
Hormone therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
14 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer